STXS Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -86.59% compared to Stereotaxis, Inc.'s net margin of 12.65%. Stereotaxis, Inc.'s return on equity of -218.3% beat Electromed, Inc.'s return on equity of 18.89%.

Stereotaxis, Inc. has a consensus price target of $4.25, signalling upside risk potential of 74.9%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.5%. Given that Stereotaxis, Inc. has higher upside potential than Electromed, Inc., analysts believe Stereotaxis, Inc. is more attractive than Electromed, Inc..

Stereotaxis, Inc. has a beta of 1.472, which suggesting that the stock is 47.244% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Stereotaxis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Stereotaxis, Inc. quarterly revenues are $7.5M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Stereotaxis, Inc.'s net income of -$6.5M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Stereotaxis, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis, Inc. is 7.16x versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -86.59% compared to Stereotaxis, Inc.'s net margin of -12.6%. Stereotaxis, Inc.'s return on equity of -218.3% beat IRIDEX Corp.'s return on equity of -155.93%.

Stereotaxis, Inc. has a consensus price target of $4.25, signalling upside risk potential of 74.9%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 115.19%. Given that IRIDEX Corp. has higher upside potential than Stereotaxis, Inc., analysts believe IRIDEX Corp. is more attractive than Stereotaxis, Inc..

Stereotaxis, Inc. has a beta of 1.472, which suggesting that the stock is 47.244% more volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.

Stereotaxis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

Stereotaxis, Inc. quarterly revenues are $7.5M, which are smaller than IRIDEX Corp. quarterly revenues of $12.5M. Stereotaxis, Inc.'s net income of -$6.5M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, Stereotaxis, Inc.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis, Inc. is 7.16x versus 0.31x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -86.59% compared to Stereotaxis, Inc.'s net margin of -36.3%. Stereotaxis, Inc.'s return on equity of -218.3% beat Myomo, Inc.'s return on equity of -68.35%.

Stereotaxis, Inc. has a consensus price target of $4.25, signalling upside risk potential of 74.9%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than Stereotaxis, Inc., analysts believe Myomo, Inc. is more attractive than Stereotaxis, Inc..

Stereotaxis, Inc. has a beta of 1.472, which suggesting that the stock is 47.244% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Stereotaxis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Stereotaxis, Inc. quarterly revenues are $7.5M, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Stereotaxis, Inc.'s net income of -$6.5M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Stereotaxis, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis, Inc. is 7.16x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -86.59% compared to Stereotaxis, Inc.'s net margin of 7.29%. Stereotaxis, Inc.'s return on equity of -218.3% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Stereotaxis, Inc. has a consensus price target of $4.25, signalling upside risk potential of 74.9%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Stereotaxis, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Stereotaxis, Inc. is more attractive than Phibro Animal Health Corp..

Stereotaxis, Inc. has a beta of 1.472, which suggesting that the stock is 47.244% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Stereotaxis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Stereotaxis, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stereotaxis, Inc. quarterly revenues are $7.5M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Stereotaxis, Inc.'s net income of -$6.5M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Stereotaxis, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis, Inc. is 7.16x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.